MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$15,790K
EPS
-$0.91
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development expenses
697
420
462
568
General and administrative expenses
1,687
2,589
1,987
1,961
Impairment of intangible assets
13,533
-
-
-
Loss from operating activities
-15,917
-3,009
-2,449
-2,529
Foreign exchange (loss) gain
-14
-7
4
-8
Change in fair value of derivative warrant liabilities
0
0
40
-1,427
Interest and other income, net
141
138
170
172
Total other income (expense), net
127
131
134
1,591
Loss before income tax benefit
-15,790
-2,878
-2,315
-938
Income tax benefit
0
-1,700
0
0
Net loss
-15,790
-1,178
-2,315
-938
Basic EPS
-0.91
-0.068
-0.14
-0.06
Diluted EPS
-0.91
-0.068
-0.14
-0.06
Basic Average Shares
17,269,986
17,259,864
16,933,620
15,924,522
Diluted Average Shares
17,269,986
17,259,864
16,933,620
15,924,522
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$15,790K
(-369.66%↓ Y/Y)
Interest and other
income, net
$141K
(-31.22%↓ Y/Y)
Loss before income
tax benefit
-$15,790K
(-369.66%↓ Y/Y)
Total other income
(expense), net
$127K
(146.69%↑ Y/Y)
Foreign exchange (loss)
gain
-$14K
(-240.00%↓ Y/Y)
Loss from operating
activities
-$15,917K
(-415.11%↓ Y/Y)
Impairment of intangible
assets
$13,533K
General and
administrative expenses
$1,687K
(-20.98%↓ Y/Y)
Research and development
expenses
$697K
(-27.02%↓ Y/Y)
Buy us a coffee
Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. (GRCE)